Cell based approaches for evaluation of drug-induced liver injury

Toxicology

Volumn 268, Issue 3, 2010, Pages 125-131

  Greer, Mhairi L ^a   Barber, Jane ^a   Eakins, Julie ^a   Kenna, J Gerry ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Bile salt export pump; Cytochrome P450; Drug induced liver injury; Mitochondrial impairment; Reactive metabolites; THLE CYP cells

Indexed keywords

BORNEOL; CHLORPROMAZINE; CIMETIDINE; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DICLOFENAC; METHAPYRILENE; METYRAPONE; PROADIFEN; SALICYLIC ACID; STREPTOMYCIN; SULFAPHENAZOLE;

CELL VIABILITY; CYTOTOXICITY; DRUG EXPOSURE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; LIVER CELL CULTURE; LIVER MITOCHONDRION; LIVER NECROSIS; LIVER TOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANIMALS; BILE; CELL SURVIVAL; CYTOCHROME P-450 ENZYME SYSTEM; DRUG-INDUCED LIVER INJURY; ENZYME INHIBITORS; HEPATOCYTES; HUMANS; MITOCHONDRIA, LIVER; TRANSFECTION;

EID: 77049121038     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2009.08.007     Document Type: Review

References (43)

1. Aoyama T., Yamano S., Guzelian P.S., Gelboin H.V., and Gonzalez F.J. Five of 12 forms of vaccinia virus-expressed human hepatic cytochrome P450 metabolically activate aflatoxin B1. Proc. Natl. Acad. Sci. U.S.A. 87 12 (1990) 4790-4793
2. de Abajo F.J., Montero D., Madurga M., and Garcia Rodriguez L.A. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br. J. Clin. Pharmacol. 58 1 (2004) 71-80
3. Barcelo S., Mace K., Pfeifer A.M., and Chipman J.K. Production of DNA strand breaks by N-nitrosodimethylamine and 2-amino-3-methylimidazo[4,5-f]quinoline in THLE cells expressing human CYP isoenzymes and inhibition by sulforaphane. Mutat. Res. 402 1-2 (1998) 111-120
4. Bort R., Ponsoda X., Jover R., Gomez-Lechon M.J., and Castell J.V. Diclofenac toxicity to hepatocytes: a role for drug metabolism in cell toxicity. J. Pharmacol. Exp. Ther. 288 1 (1999) 65-72
5. Cavin C., Mace K., Offord E.A., and Schilter B. Protective effects of coffee diterpenes against aflatoxin B1-induced genotoxicity: mechanisms in rat and human cells. Food Chem. Toxicol. 39 6 (2001) 549-556
6. Coulet M., Dacasto M., Eeckhoutte C., Larrieu G., Sutra J.F., Alvinerie M., Mace K., Pfeifer A.M., and Galtier P. Identification of human and rabbit cytochromes P450 1A2 as major isoforms involved in thiabendazole 5-hydroxylation. Fundam. Clin. Pharmacol. 12 2 (1998) 225-235
7. Dambach D.M., Andrews B.A., and Moulin F. New technologies and screening strategies for hepatotoxicity: use of in vitro models. Toxicol. Pathol. 33 1 (2005) 17-26
8. Ding S., Yao D., Burchell B., Wolf C.R., and Friedberg T. High levels of recombinant CYP3A4 expression in Chinese hamster ovary cells are modulated by coexpressed human P450 reductase and hemin supplementation. Arch. Biochem. Biophys. 348 2 (1997) 403-410
9. Doehmer J. V79 Chinese hamster cells genetically engineered for cytochrome P450 and their use in mutagenicity and metabolism studies. Toxicology 82 1-3 (1993) 105-118
10. Dunn J.C., Tompkins R.G., and Yarmush M.L. Long-term in vitro function of adult hepatocytes in a collagen sandwich configuration. Biotechnol. Prog. 7 3 (1991) 237-245
11. Dykens J.A., and Will Y. The significance of mitochondrial toxicity testing in drug development. Drug Discov. Today 12 17-18 (2007) 777-785
12. Graham E.E., Walsh R.J., Hirst C.M., Maggs J.L., Martin S., Wild M.J., Wilson I.D., Harding J.R., Kenna J.G., Peter R.M., Williams D.P., and Park B.K. Identification of the thiophene ring of methapyrilene as a novel bioactivation-dependent hepatic toxicophore. J. Pharmacol. Exp. Ther. 326 2 (2008) 657-671
13. Grancharov K., Naydenova Z., Lozeva S., and Golovinsky E. Natural and synthetic inhibitors of UDP-glucuronosyltransferase. Pharmacol. Ther. 89 2 (2001) 171-186
14. Hamilton G.A., Jolley S.L., Gilbert D., Coon D.J., Barros S., and LeCluyse E.L. Regulation of cell morphology and cytochrome P450 expression in human hepatocytes by extracellular matrix and cell-cell interactions. Cell Tissue Res. 306 1 (2001) 85-99
15. Hewitt N.J., Lechón M.J., Houston J.B., Hallifax D., Brown H.S., Maurel P., Kenna J.G., Gustavsson L., Lohmann C., Skonberg C., Guillouzo A., Tuschl G., Li A.P., LeCluyse E., Groothuis G.M., and Hengstler J.G. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab. Rev. 39 1 (2007) 159-234
16. Hopwood J., Summers C., Pognan F., Barrett G., Jones K., Laine R., and Kenna J.G. A novel method for quantification of canalicular transporter inhibition in primary rat hepatocyte sandwich cultures. Toxicology 226 1 (2006) 66-67
17. Ingelman-Sundberg M. Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn. Schmiedebergs. Arch. Pharmacol. 369 1 (2004) 89-104
18. Ju C., Reilly T.P., Bourdi M., Radonovich M.F., Brady J.N., George J.W., and Pohl L.R. Protective role of Kupffer cells in acetaminophen-induced hepatic injury in mice. Chem. Res. Toxicol. 15 12 (2002) 1504-1513
19. Kalgutkar A.S., and Soglia J.R. Minimising the potential for metabolic activation in drug discovery. Expert Opin. Drug Metab. Toxicol. 1 1 (2005) 91-142
20. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. 4 6 (2005) 489-499
21. LeCluyse E.L., Audus K.L., and Hochman J.H. Formation of extensive canalicular networks by rat hepatocytes cultured in collagen-sandwich configuration. Am. J. Physiol. 266 6 Pt 1 (1994) C1764-C1774
22. Lin J.H., and Lu A.Y. Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet. 35 5 (1998) 361-390
23. Mace K., Aguilar F., Wang J.S., Vautravers P., Gomez-Lechon M., Gonzalez F.J., Groopman J., Harris C.C., and Pfeifer A.M. Aflatoxin B1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines. Carcinogenesis 18 7 (1997) 1291-1297
24. Mills C.O., Milkiewicz P., Muller M., Roma M.G., Havinga R., Coleman R., Kuipers F., Jansen P.L., and Elias E. Different pathways of canalicular secretion of sulfated and non-sulfated fluorescent bile acids: a study in isolated hepatocyte couplets and TR-rats. J. Hepatol. 31 4 (1999) 678-684
25. Molden E., Asberg A., and Christensen H. CYP2D6 is involved in O-demethylation of diltiazem. An in vitro study with transfected human liver cells. Eur. J. Clin. Pharmacol. 56 8 (2000) 575-579
26. Mugford C.A., Mortillo M., Mico B.A., and Tarloff J.B. 1-Aminobenzotriazole-induced destruction of hepatic and renal cytochromes P450 in male Sprague-Dawley rats. Fundam. Appl. Toxicol. 19 1 (1992) 43-49
27. Park B.K., Kitteringham N.R., Maggs J.L., Pirmohamed M., and Williams D.P. The role of metabolic activation in drug-induced hepatotoxicity. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 177-202
28. Pauli-Magnus C., and Meier P.J. Hepatobiliary transporters and drug-induced cholestasis. Hepatology 44 4 (2006) 778-787
29. Pfeifer A.M., Cole K.E., Smoot D.T., Weston A., Groopman J.D., Shields P.G., Vignaud J.M., Juillerat M., Lipsky M.M., and Trump B.F. Simian virus 40 large tumor antigen-immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens. Proc. Natl. Acad. Sci. U.S.A. 90 11 (1993) 5123-5127
30. Pohl L.R., Satoh H., Christ D.D., and Kenna J.G. The immunologic and metabolic basis of drug hypersensitivities. Annu. Rev. Pharmacol. Toxicol. 28 (1988) 367-387
31. Puga A., Raychaudhuri B., Salata K., Zhang Y.H., and Nebert D.W. Stable expression of mouse Cyp1a1 and human CYP1A2 cDNAs transfected into mouse hepatoma cells lacking detectable P450 enzyme activity. DNA Cell Biol. 9 6 (1990) 425-436
32. Reers M., Smith T.W., and Chen L.B. J-aggregate formation of a carbocyanine as a quantitative fluorescent indicator of membrane potential. Biochemistry 30 18 (1991) 4480-4486
33. Ridley A.J., Allen W.E., Peppelenbosch M., and Jones G.E. Rho family proteins and cell migration. Biochem. Soc. Symp. 65 (1999) 111-123
34. Roberts R.A., Ganey P.E., Ju C., Kamendulis L.M., Rusyn I., and Klaunig J.E. Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis. Toxicol. Sci. 96 1 (2007) 2-15
35. Scheen A.J. Hepatotoxicity with thiazolidinediones: is it a class effect?. Drug Saf. 24 12 (2001) 873-888
36. Seglen P.O. Preparation of isolated rat liver cells. Methods Cell Biol. 13 (1976) 29-83
37. Selim K., and Kaplowitz N. Hepatotoxicity of psychotropic drugs. Hepatology 29 5 (1999) 1347-1351
38. Shah R.R. Can pharmacogenetics help rescue drugs withdrawn from the market?. Pharmacogenomics 7 6 (2006) 889-908
39. Shimada T., Yamazaki H., Mimura M., Inui Y., and Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270 1 (1994) 414-423
40. Stamatoglou S.C., Hughes R.C., and Lindahl U. Rat hepatocytes in serum-free primary culture elaborate an extensive extracellular matrix containing fibrin and fibronectin. J. Cell Biol. 105 5 (1987) 2417-2425
41. Trauner M., and Boyer J.L. Bile salt transporters: molecular characterization, function, and regulation. Physiol. Rev. 83 2 (2003) 633-671
42. van Montfoort J.E., Hagenbuch B., Groothuis G.M., Koepsell H., Meier P.J., and Meijer D.K. Drug uptake systems in liver and kidney. Curr. Drug Metab. 4 3 (2003) 185-211
43. Walgren J.L., Mitchell M.D., and Thompson D.C. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit. Rev. Toxicol. 35 4 (2005) 325-361